Residual Pulmonary Hypertension and Pulmonary Artery Denervation

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

Pulmonary hypertension (PH) is a rare lung disease that refers to an increase in blood pressure in the pulmonary arteries. Unfortunately, there is no known cure available to end PH, but research has been evolving and doctors and scientists have been discovering some new ways to approach this lung condition.

You might be interested in reading more about Uptravi (selexipag) as a treatment for PH.

Treatment options have been discussed and research has been evolving towards finding new ways to ease the symptoms of this condition. In this video, shared by PCR, Boris Rudenko, from Russia, discusses a promising first-in-human-study. The symplicity denervation system is regarded a possible treatment option as an effective clinical procedure for patients with residual pulmonary hypertension after pulmonary thromboembolism and surgical thrombendarterectomy.

But is this a possibility? Watch the video and learn more about Rudenko’s considerations on the subject.

Learn more about pulmonary hypertension treatment options here.


A Conversation With Rare Disease Advocates